We recognise that many of the lives of those who need our products have been touched by tragedy and are changed forever.
At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible.
PolyNovo develops innovative medical devices utilising the patented bioabsorbable polymer technology Novosorb®.
NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways.
NovoSorb BTM (Biodegradable Temporising Matrix) is the first product commercialised by PolyNovo. In 2015, following the FDA 510K clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns.
We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.
NovoSorb BTM Milestones
- ISO 13485
- CE Certificate QA System
- CE Certificate BTM
- Corporate Governance Statement
- PolyNovo Board Charter
- Market Disclosure Protocol
- PolyNovo Share Trading Policy
- Communications Policy
- Audit and Risk Committee Charter
- PolyNovo Code
- PolyNovo Gender Diversity Policy
- Rem and Nomination Committee Charter
- PolyNovo Risk Management Policy
- Commercial Code of Conduct
- Whistle-blower Policy